A first-in-human, three-part, randomized, double-blind, placebo-controlled study of SAR-443726 to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis
Latest Information Update: 03 Nov 2021
At a glance
- Drugs SAR 443726 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- 03 Nov 2021 New trial record